Stay updated with the latest foreign-investment-review-board news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on foreign-investment-review-board topics.
(Reuters) -An Australian court on Wednesday stopped U.S. drugmaker Cosette from abandoning its A$672 million ($437.6 million) takeover of Mayne Pharma, which now awaits clearance from the Foreign Investment Review Board (FIRB). The ASX-listed pharmaceutical company said on Thursday it would take all steps within its scope to implement the deal. Shares in Mayne Pharma jumped as much as 14.8% to A$6.5 at open in Sydney, but were still trading way below the A$7.40 apiece that Cosette had offered. ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.